Carmentix, U of Melbourne Launch Prenatal Biomarkers Initiative

Dec 12, 2016

NEW YORK (GenomeWeb) – Singapore-based company Carmentix Private Limited and Australia's University of Melbourne announced a new initiative last week to discover biomarkers related to preterm birth.

"Carmentix is excited to begin this collaboration, as we are keen to further develop the biomarkers discovered on our unique data mining platform," CEO Nir Arbel said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

Carmentix, U of Melbourne Launch Prenatal Biomarkers Initiative

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Guardant Health Prices $319.5M Public Stock Offering

Sponsorships